This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/mesh/concept/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01564/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01564/identifier/pubchem-compound/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01564/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01564/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01564
rdf:type
n3:Drug
n3:description
A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.
n3:generalReferences
# Meli RJ, Ros PR: MR appearance of intra-abdominal metastatic melanoma. Magn Reson Imaging. 1992;10(4):705-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1501542
n3:group
illicit experimental
n3:indication
An anabolic steroid which can theoretically aid in restauration and buildup of certain tissues, especially muscle. It is similar to synthetic testosterone and is still in early investigation. It was also investigated for use as a treatment for metastatic breast cancer.
owl:sameAs
n6:DB01564 n14:DB01564
dcterms:title
Calusterone
adms:identifier
n10:28204 n11:46507441 n12:26239 n13:DB01564
n3:mechanismOfAction
The effects of calusterone in humans most likely occur by way of two main mechanisms: by activation of the androgen receptor, and by conversion to estradiol and activation of certain estrogen receptors. Using testosterone as the prime example, free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
n3:synonym
17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one 7beta,17alpha-Dimethyltestosterone Calusteronum CLS 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one 17beta-Hydroxy-7beta,17alpha-dimethylandrost-4-ene-3-one Calusteron 7-beta,17-Dimethyltestosterone 7-beta,17-alpha-Dimethyl testosterone 7beta,17-Dimethyltestosterone Calusterona
n7:hasConcept
n8:M0197664
n3:IUPAC-Name
n4:271B560A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5610-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B560F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B560C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B560D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B560E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5608-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5606-363D-11E5-9242-09173F13E4C5 n4:271B5609-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5607-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5616-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5617-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5611-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5612-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5614-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5613-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5615-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
17021-26-0
n3:Bioavailability
n4:271B561C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B561E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B561F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5620-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B561B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B561A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B561D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B560B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5618-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5619-363D-11E5-9242-09173F13E4C5